Increased urinary phosphate excretion in pseudohypoparathyroidism type II with long-term treatment with phosphodiesterase inhibitor.

Mano, T; Uchimura, K; Hayashi, R; Kobahashi, T; Fujiwara, K; Makino, M; Kakizawa, H; Nagata, M; Nakai, A; Wada, M; Nagasaka, A; Itoh, M

Mano, T; Uchimura, K; Hayashi, R; Kobahashi, T; Fujiwara, K; Makino, M; Kakizawa, H; Nagata, M; Nakai, A; Wada, M; Nagasaka, A; Itoh, M.

Affiliation

Mano T; Department of Internal Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.

Horm Metab Res ; 31(11): 602-5, 1999 Nov.

Article in En | MEDLINE | ID: mdl-10598827

Subject(s)

Phosphates/urine; Phosphodiesterase Inhibitors/administration & dosage; Pseudohypoparathyroidism; Theophylline/administration & dosage; Bucladesine; Calcium/blood; Calcium Channel Blockers; Calcium Compounds; Cyclic AMP/urine; Female; Humans; Lactates; Middle Aged; Nifedipine; Pseudohypoparathyroidism/diagnosis; Pseudohypoparathyroidism/drug therapy; Pseudohypoparathyroidism/urine

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Aromoterapia Main subject: Phosphates / Phosphodiesterase Inhibitors / Pseudohypoparathyroidism / Theophylline Type of study: Diagnostic_studies Language: En Journal: Horm Metab Res Year: 1999 Type: Article Affiliation country: Japan

Search on Google

Add to My VHL

XML

PubMed Links